Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/j.gastro.2019.07.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection.
Inflammopharmacology
October 2024
Department of Pathology, School of Medicine, University of Zagreb, 10000, Zagreb, Croatia.
Article Synopsis
- * Clinical evidence supports BPC 157’s effectiveness in treating various conditions, including ulcerative colitis, with no side effects reported, and it demonstrates a capacity for tissue regeneration across multiple systems such as muscles, tendons, and the heart.
- * The review discusses BPC 157's role in counteracting severe complications from major vessel failures and various organ system disturbances, emphasizing its use in conditions linked to alcohol-induced stomach lesions and overall vascular recovery.
Impact of malnutrition and sarcopenia on quality of life in patients with inflammatory bowel disease: A multicentre study.
J Cachexia Sarcopenia Muscle
December 2023
Department of General Surgery, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Background: Malnutrition and subsequent alterations in body composition (BC), particularly sarcopenia, are common but not yet elucidated in patients with inflammatory bowel disease (IBD); we aimed to detail the changes in BC and the characteristics of co-occurrence of malnutrition and sarcopenia in IBD patients and to investigate its effect on quality of life.
Methods: This study was a multicentre, prospective, observational study involving four tertiary referral hospitals in China. The following data were collected from consecutive IBD inpatients: demographic information, medical history, recent weight change, handgrip strength (HGS) and BC parameters by bioelectrical impedance analysis (BIA).
Back Up at the Pump? I Have a Gut Feeling About This: A Review of the Gastrointestinal Manifestations From Congestive Heart Failure.
Cardiol Rev
December 2024
Department of Medicine & Pharmacology, Department of Medicine, New York Medical College, Valhalla, NY.
Heart failure, which is a clinical syndrome characterized by the heart's inability to maintain adequate cardiac output, is known to affect various organ systems in the body due to its ischemic nature and activation of the systemic immune response, but the resultant complications specifically on the gastrointestinal tract and the liver are not well discussed and poorly understood. Gastrointestinal-related phenomena are common symptoms experienced in patients with heart failure and frequently found to increase morbidity and mortality in these populations. The relationship between the gastrointestinal tract and heart failure are strongly linked and influence each other much so that the bidirectional association of the two is oftentimes referred to as cardiointestinal syndrome.
View Article and Find Full Text PDFTucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.
Lancet Oncol
May 2023
Mayo Clinic Arizona, Phoenix, AZ, USA. Electronic address:
Article Synopsis
- HER2 is a critical target for treatment in metastatic colorectal cancer, leading to a study evaluating the combined effects of tucatinib and trastuzumab on patients who have not responded to chemotherapy.
- The MOUNTAINEER study analyzed patients aged 18 and older with HER2-positive, RAS wild-type colorectal cancer across various sites in five countries, first as a single-cohort and later expanding participation based on interim results.
- A total of 117 patients were enrolled, with most receiving treatment in different cohorts to assess the drug's effectiveness and safety, highlighting the ongoing nature of the research and its registration on ClinicalTrials.gov.
The protective effect of IL-12/23 neutralizing antibody in sarcopenia associated with dextran sulfate sodium-induced experimental colitis.
J Cachexia Sarcopenia Muscle
April 2023
Biomedical Research Institute, Gyeongsang National University Hospital, Jinju, Republic of Korea.
Background: The improvement of colitis symptoms by treatment with IL-12/23 p40 neutralizing antibody should increase the muscle mass and the function of the sarcopenia phenotype.
Methods: An experimental colitis model was induced by oral administration of 2% dextran sulfate sodium (DSS) for 7 days. During induction of colitis, IL-12/23 p40 neutralizing antibody was injected twice on Days 3 and 5.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!